Evidence map›Paper›PMID 37034013›Full record

ArticleNature. Mental health2023

Predicting treatment resistance from first-episode psychosis using routinely collected clinical information.

Emanuele F Osimo, Benjamin I Perry, Pavan Mallikarjun, Megan Pritchard, Jonathan Lewis, Asia Katunda, Graham K Murray, Jesus Perez, Peter B Jones, Rudolf N Cardinal and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Nature. Mental health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Genetic overlap between treatment-resistant schizophrenia and smoking initiation.The international journal of neuropsychopharmacology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Emanuele F OsimoImperial College London Institute of Clinical Sciences and UKRI MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK.
Benjamin I PerryDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Pavan MallikarjunInstitute for Mental Health and Centre for Human Brain Health, University of Birmingham, Birmingham, England.
Megan PritchardSouth London and Maudsley NHS Foundation Trust, London, UK.
Jonathan LewisCambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
Asia KatundaBirmingham Early Intervention Service, Birmingham Women's and Children's NHS Foundation trust.
Graham K MurrayDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Jesus PerezDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Peter B JonesDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Rudolf N CardinalDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Oliver D HowesImperial College London Institute of Clinical Sciences and UKRI MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK.
Rachel UpthegroveInstitute for Mental Health and Centre for Human Brain Health, University of Birmingham, Birmingham, England.
Golam M KhandakerDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
University of Cambridge · GBCentre for Mental Health · GBSouth London and Maudsley NHS Foundation Trust · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBCambridgeshire and Peterborough NHS Foundation Trust · GBKing's College London · GBUniversity of East Anglia · GB

Funding

Department of Health DRF-2018-11-ST2-018Medical Research Council MC_PC_17213Medical Research Council MC_U120097115Medical Research Council MR/S037675/1Medical Research Council MR/V004905/1Medical Research Council MR/W014386/1Medical Research Council MR/W014416/1Wellcome Trust 094790Wellcome Trust 201486
6 · The paper itself

Abstract

Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-resistant schizophrenia (TRS), but there are currently no established clinically useful methods to predict this from baseline. We aimed to explore the predictive potential for clozapine use as a proxy for TRS of routinely collected, objective biomedical predictors at FEP onset, and to externally validate the model in a separate clinical sample of people with FEP. We developed and externally validated a forced-entry logistic regression risk prediction Model fOr cloZApine tReaTment, or MOZART, to predict up to 8-year risk of clozapine use from FEP using routinely recorded information including age, sex, ethnicity, triglycerides, alkaline phosphatase levels, and lymphocyte counts. We also produced a least-absolute shrinkage and selection operator (LASSO) based model, additionally including neutrophil count, smoking status, body mass index, and random glucose levels. The models were developed using data from two UK psychosis early intervention services (EIS) and externally validated in another UK EIS. Model performance was assessed via discrimination and calibration. We developed the models in 785 patients, and validated externally in 1,110 patients. Both models predicted clozapine use well at internal validation (MOZART: C 0.70; 95%CI 0.63,0.76; LASSO: 0.69; 95%CI 0.63,0.77). At external validation, discrimination performance reduced (MOZART: 0.63; 0.58,0.69; LASSO: 0.64; 0.58,0.69) but recovered after re-estimation of the lymphocyte predictor (C: 0.67; 0.62,0.73). Calibration plots showed good agreement between observed and predicted risk in the forced-entry model. We also present a decision-curve analysis and an online data visualisation tool. The use of routinely collected clinical information including blood-based biomarkers taken at FEP onset can help to predict the individual risk of clozapine use, and should be considered equally alongside other potentially useful information such as symptom scores in large-scale efforts to predict psychiatric outcomes.

Identifiers

PMID37034013
PMCPMC7614410
OpenAlexW4317499895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.